Cargando…

Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials

AIMS: To assess the therapeutic potential of fatty acid synthase (FASN) inhibition with FT‐4101, a potent, selective, orally bioavailable, small‐molecule by (a) evaluating the dose−response of single FT‐4101 doses (3, 6 and 9 mg) on hepatic de novo lipogenesis (DNL) in healthy participants (Study 1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Beysen, Carine, Schroeder, Patricia, Wu, Eric, Brevard, Julie, Ribadeneira, Maria, Lu, Wei, Dole, Kiran, O'Reilly, Terry, Morrow, Linda, Hompesch, Marcus, Hellerstein, Marc K., Li, Kelvin, Johansson, Lars, Kelly, Patrick F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898808/
https://www.ncbi.nlm.nih.gov/pubmed/33289350
http://dx.doi.org/10.1111/dom.14272
_version_ 1783653940776140800
author Beysen, Carine
Schroeder, Patricia
Wu, Eric
Brevard, Julie
Ribadeneira, Maria
Lu, Wei
Dole, Kiran
O'Reilly, Terry
Morrow, Linda
Hompesch, Marcus
Hellerstein, Marc K.
Li, Kelvin
Johansson, Lars
Kelly, Patrick F.
author_facet Beysen, Carine
Schroeder, Patricia
Wu, Eric
Brevard, Julie
Ribadeneira, Maria
Lu, Wei
Dole, Kiran
O'Reilly, Terry
Morrow, Linda
Hompesch, Marcus
Hellerstein, Marc K.
Li, Kelvin
Johansson, Lars
Kelly, Patrick F.
author_sort Beysen, Carine
collection PubMed
description AIMS: To assess the therapeutic potential of fatty acid synthase (FASN) inhibition with FT‐4101, a potent, selective, orally bioavailable, small‐molecule by (a) evaluating the dose−response of single FT‐4101 doses (3, 6 and 9 mg) on hepatic de novo lipogenesis (DNL) in healthy participants (Study 1) and (b) demonstrating the safety, tolerability and efficacy on hepatic steatosis after 12 weeks of FT‐4101 dosing in patients with non‐alcoholic fatty liver disease (NAFLD; Study 2). MATERIALS AND METHODS: In Study 1, three sequential cohorts of healthy men (n = 10/cohort) were randomized to receive a single dose of FT‐4101 (n = 5/cohort) or placebo (n = 5/cohort) followed by crossover dosing after 7 days. Hepatic DNL was assessed during fructose stimulation from (13)C‐acetate incorporation. In Study 2, men and women with NAFLD (n = 14) randomly received 12 weeks of intermittent once‐daily dosing (four cycles of 2 weeks on‐treatment, followed by 1 week off‐treatment) of 3 mg FT‐4101 (n = 9) or placebo (n = 5). Steady‐state DNL based on deuterated water labelling, hepatic steatosis using magnetic resonance imaging‐proton density fat fraction and sebum lipids and circulating biomarkers were assessed. RESULTS: Single and repeat dosing of FT‐4101 were safe and well tolerated. Single FT‐4101 doses inhibited hepatic DNL dose‐dependently. Twelve weeks of 3 mg FT‐4101 treatment improved hepatic steatosis and inhibited hepatic DNL. Decreases in sebum sapienate content with FT‐4101 at week 11 were not significant compared to placebo and rebounded at week 12. Biomarkers of liver function, glucose and lipid metabolism were unchanged. CONCLUSIONS: Inhibition of FASN with 3 mg FT‐4101 safely reduces hepatic DNL and steatosis in NAFLD patients.
format Online
Article
Text
id pubmed-7898808
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-78988082021-03-03 Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials Beysen, Carine Schroeder, Patricia Wu, Eric Brevard, Julie Ribadeneira, Maria Lu, Wei Dole, Kiran O'Reilly, Terry Morrow, Linda Hompesch, Marcus Hellerstein, Marc K. Li, Kelvin Johansson, Lars Kelly, Patrick F. Diabetes Obes Metab Original Articles AIMS: To assess the therapeutic potential of fatty acid synthase (FASN) inhibition with FT‐4101, a potent, selective, orally bioavailable, small‐molecule by (a) evaluating the dose−response of single FT‐4101 doses (3, 6 and 9 mg) on hepatic de novo lipogenesis (DNL) in healthy participants (Study 1) and (b) demonstrating the safety, tolerability and efficacy on hepatic steatosis after 12 weeks of FT‐4101 dosing in patients with non‐alcoholic fatty liver disease (NAFLD; Study 2). MATERIALS AND METHODS: In Study 1, three sequential cohorts of healthy men (n = 10/cohort) were randomized to receive a single dose of FT‐4101 (n = 5/cohort) or placebo (n = 5/cohort) followed by crossover dosing after 7 days. Hepatic DNL was assessed during fructose stimulation from (13)C‐acetate incorporation. In Study 2, men and women with NAFLD (n = 14) randomly received 12 weeks of intermittent once‐daily dosing (four cycles of 2 weeks on‐treatment, followed by 1 week off‐treatment) of 3 mg FT‐4101 (n = 9) or placebo (n = 5). Steady‐state DNL based on deuterated water labelling, hepatic steatosis using magnetic resonance imaging‐proton density fat fraction and sebum lipids and circulating biomarkers were assessed. RESULTS: Single and repeat dosing of FT‐4101 were safe and well tolerated. Single FT‐4101 doses inhibited hepatic DNL dose‐dependently. Twelve weeks of 3 mg FT‐4101 treatment improved hepatic steatosis and inhibited hepatic DNL. Decreases in sebum sapienate content with FT‐4101 at week 11 were not significant compared to placebo and rebounded at week 12. Biomarkers of liver function, glucose and lipid metabolism were unchanged. CONCLUSIONS: Inhibition of FASN with 3 mg FT‐4101 safely reduces hepatic DNL and steatosis in NAFLD patients. Blackwell Publishing Ltd 2020-12-21 2021-03 /pmc/articles/PMC7898808/ /pubmed/33289350 http://dx.doi.org/10.1111/dom.14272 Text en © 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Beysen, Carine
Schroeder, Patricia
Wu, Eric
Brevard, Julie
Ribadeneira, Maria
Lu, Wei
Dole, Kiran
O'Reilly, Terry
Morrow, Linda
Hompesch, Marcus
Hellerstein, Marc K.
Li, Kelvin
Johansson, Lars
Kelly, Patrick F.
Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
title Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
title_full Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
title_fullStr Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
title_full_unstemmed Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
title_short Inhibition of fatty acid synthase with FT‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: Results from two early‐phase randomized trials
title_sort inhibition of fatty acid synthase with ft‐4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non‐alcoholic fatty liver disease: results from two early‐phase randomized trials
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898808/
https://www.ncbi.nlm.nih.gov/pubmed/33289350
http://dx.doi.org/10.1111/dom.14272
work_keys_str_mv AT beysencarine inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT schroederpatricia inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT wueric inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT brevardjulie inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT ribadeneiramaria inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT luwei inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT dolekiran inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT oreillyterry inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT morrowlinda inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT hompeschmarcus inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT hellersteinmarck inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT likelvin inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT johanssonlars inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials
AT kellypatrickf inhibitionoffattyacidsynthasewithft4101safelyreduceshepaticdenovolipogenesisandsteatosisinobesesubjectswithnonalcoholicfattyliverdiseaseresultsfromtwoearlyphaserandomizedtrials